Based on these studies, it may be possible to treat glioma patients with hn RNPA2/B1 gene inhibitors in the future, which is expected to greatly improve the therapeutic effect of glioma and increase the long-term survival of patients. This evidence concerns the gene HNRNPA2B1 and central nervous system cancer.